Tocagen is a clinical-stage biopharmaceutical company pursuing the discovery, development and commercialization of products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatment currently exists. The Company believes that cancer selective immunotherapies represent an important opportunity for treating cancers because such therapeutics selectively activate the immune system against the tumor both locally and systemically.
The Company uses a simple retrovirus as a proprietary platform to develop a novel set of gene transfer products which deliver therapeutic genes to cancer cells. We believe the product candidates being developed by us could be more effective, with fewer side effects, than other cancer immunotherapeutic approaches as well as many current conventional cancer treatment approaches.
Tocagen is initially focusing on treatments for brain cancer patients for whom we believe no adequate treatment currently exists. Potential future indications may include metastatic cancers including melanoma and colorectal cancer.